RecruitingPhase 3NCT06963827
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takeda
- Principal Investigator
- Study DirectorTakeda
- Intervention
- Mezagitamab(drug)
- Enrollment
- 347 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (30)
- UAB Nephrology Research Clinic at Paula Building, Birmingham, Alabama, United States
- DCR Montgomery, Montgomery, Alabama, United States
- Academic Medical Research Institute, Los Angeles, California, United States
- University of California Irvine, Orange, California, United States
- South Florida Research Institute, Lauderdale Lakes, Florida, United States
- Bioresearch Partners, Miami, Florida, United States
- CTR Oakwater, LLC, Orlando, Florida, United States
- Bioresearch Partners, Pembroke Pines, Florida, United States
- DCR Columbus, Columbus, Georgia, United States
- CARE Institute - Boise Kidney, Boise, Idaho, United States
- Northwest Louisiana Nephrology, Shreveport, Louisiana, United States
- Ingham Nephrology & Hypertension, P.C., Lansing, Michigan, United States
- Elixia MKC, Pontiac, Michigan, United States
- DCR Edina, Edina, Minnesota, United States
- Elixia MNA, City of Saint Peters, Missouri, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06963827 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital